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Abstract
Background: Transcatheter edge‐to‐edge repair (TEER) with MitraClip improves
outcomes among select patients with moderate–to‐severe and severe mitral re-
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gurgitation; however, data regarding sex‐specific differences in the outcomes among
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patients undergoing TEER are limited.
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Methods: An electronic search of the PubMed, Embase, Central, and Web of Science
databases for studies comparing sex differences in outcomes among patients undergoing TEER was performed. Summary estimates were primarily conducted using a
random‐effects model.
Results: Eleven studies with a total of 24,905 patients (45.6% women) were included. Women were older and had a lower prevalence of comorbidities, including
diabetes, chronic kidney disease, and coronary artery disease. There was no difference in procedural success (odds ratio [OR]: 0.75, 95% confidence interval [CI]:
0.55–1.05) and short‐term mortality (i.e., up to 30 days) between women and men
(OR: 1.16, 95% CI: 0.97–1.39). Women had a higher incidence of periprocedural
bleeding and stroke (OR: 1.34, 95% CI: 1.15–1.56) and (OR: 1.57, 95% CI:
1.10–2.25), respectively. At a median follow‐up of 12 months, there was no difference in mortality (OR: 0.98, 95% CI: 0.89–1.09) and heart failure hospitalizations
(OR: 1.07, 95% CI: 0.68–1.67). An analysis of adjusted long‐term mortality showed a
lower incidence of mortality among women (hazards ratio: 0.77, 95% CI: 0.67–0.88).
Conclusions: Despite a lower prevalence of baseline comorbidities, women undergoing TEER with MitraClip had higher unadjusted rates of periprocedural stroke and
bleeding as compared with men. There was no difference in unadjusted procedural
success, short‐term or long‐term mortality. However, women had lower adjusted
mortality on long‐term follow‐up. Future high‐quality studies assessing sex differences in outcomes after TEER are needed to confirm these findings.
KEYWORDS

MitraClip, outcomes, percutaneous mitral valve repair, sex differences, transcatheter edge‐to‐
edge mitral valve repair

Abbreviations: CI, confidence interval; HR, hazards ratio; MR, mitral regurgitation; OR, odds ratio; TEER, transcatheter edge‐to‐edge repair.
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| INTRODUCTION

YA et al.

were required to report sex‐specific outcomes between women and
men. Studies not reporting sex‐specific outcomes were excluded. If a

Transcatheter edge‐to‐edge mitral valve repair (TEER), using

study population was utilized in more than one publication, we in-

MitraClip, is a therapeutic option for select patients with sympto-

cluded the study with the largest population or the one with the

matic moderate‐to‐severe or severe (Grade 3+ or 4+) mitral regur-

longest available follow‐up.

gitation (MR), whether functional or degenerative.1–8 In the 2020
American College of Cardiology/American Heart Association (ACC/
AHA) valvular heart disease guidelines, TEER is given a class IIa

2.3 |

Data extraction

recommendation for severe primary MR among patients with prohibitive or high‐risk for surgery together with feasible anatomy and life
2

Data including study design, baseline characteristics, clinical out-

expectancy of at least 1 year. Similarly, TEER is endosed as a Class

comes of both unadjusted and maximally adjusted data when avail-

IIa recommendation for symptomatic cardiomyopathy patients and

able were independently extracted by two authors (Lina Ya'Qoub and

chronic severe secondary MR despite optimal guideline‐directed

Rawan Ya'acoub). Any discrepancy was resolved by consensus among

medical therapy (GDMT).

2

the authors.

Few studies have assessed the sex differences in the clinical
profile and outcomes of TEER.3–16 While some studies showed that
women and men undergoing TEER do not share a similar clinical

2.4 |

Outcomes

profile, studies also showed conflicting findings regarding the outcomes after TEER. For example, some studies suggested that women

The outcomes assessed in this study were classified as short‐term

have a higher risk of short‐term mortality and bleeding,6,9 but these

(i.e., up to 30 days), and long‐term (i.e., reported at the longest

findings were not replicated in other studies.3–5 To better address

available duration of follow‐up). Short‐term outcomes included: all‐

this knowledge gap, we aimed to conduct a comprehensive meta‐

cause mortality, stroke, bleeding, and procedural success rate. The

analysis to compare the outcomes between women and men un-

definition of stroke and bleeding was according to the individual

dergoing TEER with MitraClip.

studies. Procedural success was defined as residual MR of Grade 2 or
less.3–14 The long‐term outcomes included: all‐cause mortality, heart
failure (HF) hospitalization, and residual MR of ≥Grade 3 on sub-

2
2.1

| M E TH O D S

sequent imaging.

| Data sources
2.5 |

Quality assessment

An electronic search of the MEDLINE, Embase, Central, and Web of
Science was performed from inception until November 2021 without

The Newcastle–Ottawa scale was used to assess the risk of bias of

language restriction, using the keywords: “mitral valve clip,” “Mi-

each study included. A study was considered of high quality if

traClip,” “MVR”, or “percutaneous mitral valve repair,” and “sex” or

achieved 7 out of 9 points. The scale is based on three main com-

“gender” (Table S1). Bibliographies of the included studies, relevant

ponents: selection of the case/control and their representativeness,

review articles, and meta‐analyses were manually searched for any

comparability of cases and controls based on design and analysis, and

potential missed studies. The major cardiovascular conferences and

ascertainment of exposure and outcome.19 A study is awarded a star

proceedings, including the ACC and AHA scientific sessions, were

for each component in the selection and exposure sections and a

also screened for any abstracts addressing this topic. This meta‐

maximum of two stars in the comparability section.

analysis was registered with the International Prospective Register
for Systemic Reviews (CRD42021236447) and conducted according
to the meta‐analysis of observational studies in the epidemiology

2.6 |

Statistical analysis

group and the preferred reporting items for systematic reviews and
meta‐analyses guidelines.17,18 The data that support the findings of

All descriptive analyses were conducted using weighted means and

this study are available from the corresponding author upon rea-

ranges for continuous variables and weighted frequencies for cate-

sonable request.

gorical variables with the weight corresponding to the sample size of
each study. For each outcome, an unadjusted summary odds ratio
(OR) was calculated using the reported events. Both unadjusted and

2.2

| Selection criteria

adjusted outcomes were calculated by the random‐effects model
using the Der–Simonian and Laird model. A secondary analysis using

Randomized clinical trials, prospective and retrospective cohort stu-

the fixed‐effects model was also conducted. The degree of statistical

dies, as well as case‐control studies, comparing sex‐specific outcomes

heterogeneity was evaluated by I2 statistics. A sensitivity analysis

among adults undergoing TEER, were included. To be eligible, studies

excluding the largest study was conducted to determine its effect on

|

YA et al.

3

the summary estimates. Publication bias was not assessed since the

from in‐hospital to 24 months (weighted median follow‐up

number of included studies for each outcome was <10 studies.20 All

duration was 12 months).

analyses were considered statistically significant if the p < 0.05 and all

Overall, six studies were determined as high quality by the

effect sizes were calculated with a 95% confidence interval (CI). The

Newcastle–Ottawa scale while the other five were considered as

statistical analysis was conducted using R studio software (2020;

low‐intermediate quality. In this scale index, the domains of highest

Integrated Development for R and RStudio, Inc.).

susceptibility to bias were exposure/outcome followed by comparability (Table S2).
The baseline characteristics of the included subjects are shown in

3

| RESULTS

Table 2. The mean Society of Thoracic Surgery score was 6.2, and the
mean logistic EuroSCORE was 21.1 (Table 2). In most studies, women

| Included studies

3.1

were older, had higher mean ejection fraction and higher rates of
New York Heart Association Class III/IV HF at baseline. Risk profile in

The initial search yielded 2218 articles, of which 2205 were excluded

men differed, with overall higher rates of certain comorbidities, such

on the revision of the titles and abstracts. Among the remaining 13

as diabetes mellitus, chronic kidney disease, coronary artery disease,

studies, 3 studies were driven from the National Inpatient Sample

or prior myocardial infarction than women (Table 2).

database,11,15,16 thus we included the study with the largest sample

The proportions of functional and degenerative MR were dif-

size.11 Eleven studies with 24,905 patients were included in the final

ferent among the studies.3,4,6,10,12–14 Gafoor et al.6 included a high

analysis. Of which, 11,346 were females (45.6%) and 13,559 were

proportion of patients with functional MR (68% among women and

males (54.4%).3–14 The study flow diagram is summarized in Figure 1.

86% among men). Paulus et al.10 included 92.4% with secondary MR

The study characteristics are summarized in Table 1. The in-

and 7.6% with MR of mixed etiology. In the study by Villablanca

cluded studies were from Europe, United States, and Canada.

et al.,12 87.5% of patients had degenerative MR, while functional MR

One study was a secondary analysis of a randomized clinical

rate comprised 17.6% of patients. Two other studies reported the

trial,

14

3–7,9–14

Eight of

proportion of patients with functional MR, 75.4% among women and

the studies were multicenter, while the remainder were

82.1% among men in one study,3 and 48% among women and 58%

single‐center studies (Table 1). The follow‐up duration ranged

among men in the other.4

and the rest were observational studies.

F I G U R E 1 Preferred reporting items for
systematic reviews and meta‐analyses flow
diagram summarizing the search strategy and
included studies [Color figure can be viewed at
wileyonlinelibrary.com]
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TABLE 1

Characteristics for each study included in the analysis

Study (References)

Year
published

Study type

Single/
multicenter

Countries

Enrollment period

Attizzani et al.3

2015

Prospective

Single‐center

Italy

2008–2013

65

106

12

Estevez‐Loureiro
et al.4

2015

Retrospective

Multicenter

UK, Denmark, Sweden 2009–2012

64

109

16

Giordano et al.5

2015

Retrospective

Multicenter

Italy

NR

45

39

12

2016

Prospective

Multicenter

Europe

2008–2011

205

362

12

6

Gafoor et al.

7

Follow‐up,
Females Males months

2016

Prospective

Single‐center

Germany

2008–2015

230

362

24

9

2019

Prospective

Multicenter

Germany

2010–2013

327

501

12

10

2020

Retrospective

Single‐center

Germany

2011–2019

37

42

1

2020

Retrospective

Multicenter

US

2010–2017

7184

8080

0

2021

Retrospective

multicenter

US

2013–2017

2523

2772

12

2021

Retrospective

Multicenter

Europe

2008–2018

445

788

24

2021

Prospective

Multicenter

US

2012–2017

221

393

24

Tigges et al.

Werner et al.
Paulus et al.

11

Khan et al.

12

Villablanca et al.
13

Park et al.

Kosmidou et al.

14

Abbreviations: NR, not reported; US, United States.

3.2

| Short‐term outcomes

Valve Academic Research Consortium criteria: a drop in the
hemoglobin of 3.0 g/dl or requiring transfusion of 3 units of whole

Eight studies reported short‐term mortality with a total of 23,608

blood or packed red blood cells. Women had higher unadjusted rates

patients (46.0% women).3–6,9,11–13 There was no difference in the

of bleeding compared with men (OR: 1.34, 95% CI: 1.15–1.56;

incidence of all‐cause mortality between women and men (OR: 1.16,

I2 = 0%). The secondary analysis with the fixed‐effect model de-

95% CI: 0.97–1.39; I2 = 11%). The secondary analysis with a fixed‐

monstrated comparable findings (Figure 2C).

effect model demonstrated comparable findings (Figure 2A). The

Seven studies provided sex‐specific procedural success rates for

sensitivity analysis excluding the largest study showed consistent

3648 patients (37.9% women).3–7,9,13 Overall, there was no differ-

findings (OR: 1.17, 95% CI: 0.85–1.61; I2 = 24%) (Supporting

ence in procedural success rate (OR: 0.75, 95% CI: 0.55–1.05;

Information Figure Panel A).11 Analysis of the three studies which

I2 = 0%). The analysis using the fixed‐effect model showed consistent

reported adjusted short‐term mortality showed no difference in the

findings (Figure 2D).

adjusted short‐term mortality (adjusted hazard ratio [HR]: 1.11, 95%
CI: 0.94–1.33) (Figure 4A).11–13
A total of six studies reported periprocedural stroke events with

3.3 |

Long‐term outcomes

22,254 patients (46.5% women).3,4,6,9,11,12 There was no clear definition for stroke in these studies with the exception of Villablanca

Eight studies reported sex‐specific long‐term mortality, with a

et al.12 defining stroke as per the Valve Academic Research

total of 8499 patients (43.6% women), 3–6,9,12–14 while five stu-

Consortium 2 criteria as “duration of a focal or global neurological

dies reported adjusted mortality.5,6,12–14 There was no difference

deficit ≥24 h; or <24 h if available neuroimaging documents a new

in the incidence of unadjusted mortality (OR: 0.98, 95% CI:

hemorrhage or infarct; or the neurological deficit results in

0.89–1.09; I 2 = 0%) (Figure 3A). Women had lower incidence of

death.” Compared with men, women had higher odds of unadjusted

all‐cause mortality using the maximally adjusted summary esti-

2

stroke (OR: 1.57, 95% CI: 1.10–2.25; I = 0%). The analysis using the

mates (adjusted HR: 0.77, 95% CI: 0.67–0.88; I2 = 0%) (Figure 4B).

fixed‐effect model showed consistent findings (Figure 2B). The

The analysis using the fixed‐effect model showed consistent

sensitivity analysis excluding the largest study showed comparable

findings.

findings (OR: 1.20, 95% CI: 0.74–1.96; I2 = 0%) (Supporting Information Figure Panel B).

11

patients (44.2% women).3–5,9,14 There was no difference in the in-

Four studies reported periprocedural bleeding events with a total
of 6816 patients (45.5% women).

Five studies reported HF hospitalizations with a total of 1180

3,6,9,12

There was no uniform defi6

cidence of HF hospitalization (OR: 1.07, 95% CI: 0.68–1.67; I2 = 40%)
(Figure 3B).

reported

Seven studies reported residual MR (Grade 3 or 4) on follow‐up,

“bleeding complications,” Attizini et al.3 reported “blood transfu-

with a total of 6913 patients (45.0% women).3,4,6,7,12–14 There was

sion,” and Werner et al.9 reported “transfusion or major bleed-

no difference in the incidence of residual MR (OR: 1.13, 95% CI:

ing.” Villablanca et al.12 defined major bleeding as per the Mitral

0.85–1.49; I2 = 24%) (Figure 3C).

nition for bleeding across the studies. Gafoor et al.

9

73.8

69.5

Kosmidou
et al.14

77.8

64.9

85.8

48.6

62.2

61.2

73.9

NR

71.1

64.1

73.8

81.9

66.2

86.7

50.0

69.0

64.7

70.2

NR

84.6

60.6

74.5

Hypertension (%)
F
M

38.9

24.7

22.9

9.7

27.0

33.3

19.6

NR

22.2

10.9

36.9

36.4

31.3

27.3

11.1

35.7

27.7

32.9

NR

41.0

25.7

34.0

Diabetes
Mellitus (%)
F
M

36.7

18.9

19.7

NR

NR

21.9

21.8

21

22.7

20

20

59.8

30.6

31

NR

NR

31.2

40.4

38

60.5

46

42.5

Prior MI (%)
F
M

52.5

NR

39.7

51.4

48.6

66.7

50.4

44

NR

NR

NR

84

NR

62.3

67.5

69

83.9

73.5

73

NR

NR

NR

CVD (%)
F
M

31.6

40

58

NR

49

NR

46.5

NR

44

48.1

38.4

31.1

33

53

NR

42

NR

39

NR

33

42.8

34.6

Ejection
fraction, mean
F
M

50.2

79

60.6

69

3.4

a

2.3

42.9
a

73.8

47.3

63.5

46.1

38.5

NR

43.4

30.2

54.1

29.7

45.7

34.1

31.1

NR

55.4

Chronic kidney
disease (%)
F
M

66.5

87.4

85.7

NR

97.2

87.2

NR

83.9

100

96.9

83.1

57.7

88.3

82.3

NR

92.9

85.8

NR

81.2

100

94.5

80.2

Baseline NYHA
III/IV (%)
F
M

100

94.6

19.3

NR

100

87.8

NR

97.1

80

NR

95.4

100

95.4

13.9

NR

100

88.2

NR

98.1

92.3

NR

98.1

Baseline +3/+4
MR (%)
F
M

NR

NR

6.2

NR

NR

8.3

4.25

NR

4.6

NR

6.58

Mean STS
score (%)

NR

21

NR

NR

19.5

24.45

21.2

23.15

NR

18.9

NR

Mean
Euro‐
score (%)

a

End‐stage renal disease on dialysis.

Abbreviations: CVD, cardiovascular disease; MI, myocardial infarction; MR, mitral regurgitation; NR, not reported; NYHA, New York Heart Association; STS Society of Thoracic Surgery; TEER, transcatheter
edge‐to‐edge repair.

72

76

Park et al.13

82

79

76

74.2

74.4

83

80

76

77

76

72

Villablanca
et al.12

Khan et al.

11

Paulus et al.

10

Werner et al.

Tigges et al.

7

76

78

Giordano et al.5

Gafoor et al.

73.5

78.9

Estevez‐
Loureiro
et al.4

73

70.3

74.0

Attizzani et al.3

6

Mean age (y)
F
M

Baseline characteristics of patients undergoing TEER using MitraClip in each of the studies

Study
(References)

TABLE 2

YA et al.

|
5

6

|

YA et al.

F I G U R E 2 Forest plot of short‐term outcomes, including (A) mortality, (B) periprocedural stroke, (C) bleeding, and (D) procedural success
rate. CI, confidence interval; OR, odds ratio [Color figure can be viewed at wileyonlinelibrary.com]

Six studies reported HF hospitalization or mortality with a total
3–6,9,14

at baseline; and iii) there was no difference between women and men

There was no difference in the in-

in the unadjusted mortality and HF hospitalization at a median

cidence of HF or mortality (OR: 1.05, 95% CI: 0.79–1.39; I2 = 42%)

follow‐up of 12 months. However, women had a lower incidence of

(Figure 3D).

adjusted mortality.

of 1264 patients (44.9%).

Moderate‐to‐severe and severe MR, whether functional or
degenerative, is associated with an increased risk of HF hospi-

4

| DISC US SION

talizations and mortality.1–8 Studies have shown that mitral valve
repair, using surgery or transcatheter techniques for patients who

In this meta‐analysis of 11 studies with 24,905 patients, we examined

are not candidates for surgery or at high risk for surgery, im-

the sex differences in clinical profile and outcomes among patients

proves outcomes.3–14 As such, TEER using MitraClip is now

undergoing TEER with MitraClip. The salient findings of this meta‐

classified as a reasonable option for a subset of patients in the

analysis were: i) there was no difference in the rates of procedural

2020

ACC/AHA

valvular

heart

disease

guidelines.2

The

success rate and short‐term mortality between women and men; ii)

endovascular valve edge‐to‐edge repair study (EVEREST II) trial

women appear to have a higher rate of periprocedural bleeding and

was the first trial to show the efficacy and safety of TEER using

stroke, despite having a lower prevalence of comorbidities such as

MitraClip for MR compared with surgery.1 Subsequently, the

coronary artery disease, chronic kidney disease and diabetes mellitus

Cardiovascular

Outcomes

Assessment

of

the

MitraClip

|

YA et al.

7

F I G U R E 3 Forest plot showing odds ratio (OR) of studies reporting long‐term outcomes (A) mortality, (B) heart failure (HF) hospitalization,
(C) residual significant mitral regurgitation (Grade +3 or +4), and (D) mortality or HF hospitalization. CI, confidence interval [Color figure can be
viewed at wileyonlinelibrary.com]

Percutaneous Therapy (COAPT) trial demonstrated a long‐term

mortality. However, the interpretation of this finding is limited

survival benefit of TEER with MitraClip over guideline directed

given that this analysis was driven by five studies, and one study

medical treatment alone for secondary MR among symptomatic

contributed to the main weight of that analysis.

patients despite maximally tolerated medical therapy. 8 In a sex‐

Some studies suggest that the benefit of TEER is mainly ob-

specific analysis of the COAPT study, TEER improved clinical

served among patients with “disproportionate” MR (i.e., patients with

outcomes compared with guideline directed medical treatment

higher regurgitant volume relative to left ventricular end‐diastolic

alone, irrespective of sex. However, the impact of TEER in re-

volume).21–26 However, this alone does not completely account for

ducing HF hospitalization was less pronounced among women

the difference in the outcomes after TEER.21 A secondary analysis of

compared with men beyond 1 year.

14

In this context, our meta‐

the COAPT trial suggested that the effective regurgitant orifice area

analysis showed no difference between men and women in

to the left ventricular end‐diastolic dysfunction may not be the best

the unadjusted long‐term mortality or HF hospitalization at

factor associated with TEER benefit in regard to all‐cause mortality

12 months. Using the maximally adjusted summary estimates,

and HF hospitalizations.27 Additionally, some authors suggested that

women appeared to have a lower incidence of long‐term

sex might influence the outcomes following TEER; as women tend to

8

|

YA et al.

F I G U R E 4 Forest plot of hazard ratios for adjusted short‐term (A) and long‐term (B) mortality. Khan et al.11 adjusted for age and other
comorbidities: HF, CAD, coagulopathy, diabetes (with complications), hypertension (HTN), PVD, pulmonary hypertension, renal failure, smoking,
prior percutaneous coronary intervention (PCI), and prior coronary artery bypass graft (CABG). Park et al.13 adjusted for body surface area (BSA);
body mass index; PCI; CABG; transient ischemic attack (TIA); chronic obstructive pulmonary disease (COPD); or atrial fibrillation (A fib) or atrial
flutter (A flutter); left ventricular ejection fraction (LVEF); left ventricular end‐diastolic volume; left ventricular end‐systolic volume; effective
regurgitant orifice area; and mitral regurgitation. Villablanca et al.12 adjusted for age, race, BSA, prior myocardial infarction, prior
revascularization, prior cardiac operations, HTN, diabetes mellitus, any A fib or A flutter, prior stroke or TIA, prior peripheral arterial disease,
carotid stenosis, dialysis, severe chronic lung disease, home oxygen, immunocompromised status, endocarditis, current/recent smoker, New
York Heart Association functional Class IV, glomerular filtration rate, hemoglobin, LVEF, left ventricular systolic internal dimension, left
ventricular diastolic internal dimension, left main stenosis of 50% or more, triple vessel disease, hostile chest, porcelain aorta, prior mitral valve
procedure, prior nonmitral valve procedure, mitral etiology (degenerative vs. functional), mean mitral valve gradient, mitral leaflet calcification,
mitral annular calcification, aortic insufficiency (moderate/severe vs. other), procedural acuity (elective vs. urgent vs. shock or inotropes or assist
device vs. emergency or salvage or cardiac arrest) and years performing procedure. Giordano et al.5 adjusted for the following factors: age,
height, BSA, prior myocardial infarction, prior percutaneous coronary intervention, prior CABG, prior arrhythmia device implantation, ischemic
cardiomyopathy, COPD, and LVEF. Gafoor et al.6 adjusted for age, renal disease, and COPD. CAD, coronary artery disease; CI, confidence
interval; HF, heart failure; PVD, peripheral vascular disease [Color figure can be viewed at wileyonlinelibrary.com]

have significantly smaller left ventricles thus higher rates of dis-

and reporting sex‐specific data in future trials to bridge this cri-

proportionate MR relative to their small left ventricles.21 Persistent

tically important knowledge gap. 30

sex differences in left ventricular size even after adjusting for body

Studies have shown that women tend to have a higher risk of

surface area suggest that the use of sex‐specific echocardiographic

bleeding and stroke following percutaneous cardiac procedures, in-

values may potentially improve the identification of women that are

cluding transcatheter aortic valve replacement and percutaneous

most likely to benefit from TEER.21–26

coronary interventions.31–36 Not only do women tend to have an

Mitral valve prolapse is more frequently encountered among

increased risk for peri‐procedural stroke, but also tend to have worse

In addition, MR secondary to atrial dilation and re-

recovery after stroke compared with men.30,32 Consistent with other

modeling (also known as “atrial MR”) is more common among

studies, this analysis showed that women had higher rates of peri-

women, and it is unclear whether TEER is beneficial for this

procedural stroke.30,32 The higher rates of stroke could be attributed

specific entity.21,28 It is worth mentioning that women's enroll-

to the older age of women, as well as the higher incidence of atrial

ment in the landmark TEER trials has been low. Women com-

arrhythmias, including atrial fibrillation, which is more common in

promised approximately one‐third of patients in the TEER group

women, and could have potentially attributed to the higher rate of

in both the EVEREST II and COAPT trials, and even lower in the

stroke; however, this information was not reported by most of the

1,8,29

In addition, only one of these

included studies.29,31 Additionally, our analysis was consistent with

women.

25

MIRTA‐FR trial (around 21%).

landmark trials reported sex‐specific data in the clinical profile

prior studies showing higher rates of bleeding in women following

and outcomes of patients undergoing TEER. Our findings high-

cardiac procedures.31–34 This might have also been attributed to the

light the importance of recruiting a greater proportion of women

older age women as well as the lower body weight among women.31

|
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Importantly, there was no difference in the long‐term mortality between women and men, despite women having higher rates of

RE F ER EN CES
1.

periprocedural complications, including stroke and bleeding. Nevertheless, future studies addressing these potential confounders to

2.

assess sex‐specific outcomes are needed to understand the true
impact of sex on these complications following TEER.37

5

| L IM I TAT I ONS

3.

This analysis should be interpreted in the context of some limitations. First, the majority of the studies included in this analysis
are nonrandomized studies. Second, individual‐patient data were

4.

not available, precluding adjustment for differences in clinical or
anatomical variables or comparisons of severity or risk across the
cohorts. Third, most outcomes (except short and long‐term
mortality)

were

unadjusted

since

the

individual

5.

studies

did not report these adjusted outcomes, raising concern for potential confounding and selection bias. Fourth, there was no clear

6.

definition for stroke or bleeding by most of the studies. Fifth,
there was some degree of variation in the follow‐up between
the

studies.

Sixth,

the

impact

of

medications,

including

7.

guideline directed medical treatment for HF and antithrombotic
medications, could not be assessed since these were not
reported

by

the

studies.

Lastly,

the

echocardiographic

8.

parameters and type of MR at baseline were not consistently
reported in most studies. In addition, there were no core labs to
validate the reported results in the registries. As such the impact

9.

of the baseline echocardiographic measurements could not be
assessed.
10.

6

| C ONC LUS I ON

In this meta‐analysis of 11 studies reporting sex‐specific out-

11.

comes for patients undergoing TEER, we found that there was no
difference in procedural success, short‐term mortality, or long‐
term outcomes between women and men undergoing TEER with

12.

MitraClip. Women had a lower prevalence of baseline comorbidities, but higher rates of periprocedural stroke and
bleeding. Women had a lower incidence of adjusted long‐term
mortality. Future high‐quality studies assessing sex‐specific out-

13.

comes following TEER using MitraClip are needed.
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